Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07339345

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

Prospective Single-Arm Clinical Trial of Golidocitinib Monotherapy for Hemophagocytic Lymphohistiocytosis.

Status
Recruiting
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
28 (estimated)
Sponsor
Beijing Friendship Hospital · Academic / Other
Sex
All
Age
14 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.

Conditions

Interventions

TypeNameDescription
DRUGGolidocitinibAdminister the GO regimen to HLH patients who meet the inclusion criteria, specifically Golicitinib 150 mg once daily.

Timeline

Start date
2025-06-27
Primary completion
2026-06-27
Completion
2027-06-27
First posted
2026-01-14
Last updated
2026-01-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07339345. Inclusion in this directory is not an endorsement.